Hepatotoxicity of Alogliptin

Clinical Pharmacokinetics

Volumn 53, Issue 11, 2014, Pages 1055-1056

  Barbehenn, Elizabeth ^a   Almashat, Sammy ^a   Carome, Michael ^a   Wolfe, Sidney ^a  

^a Public Citizen   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALOGLIPTIN; ASPARTATE AMINOTRANSFERASE; PLACEBO; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; FULMINANT HEPATIC FAILURE; HUMAN; JAPAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; AGONISTS; LIVER DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; LIVER DISEASES; RECEPTORS, GLUCAGON;

EID: 84922082810     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0199-1     Document Type: Letter

References (11)

1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014 [Epub ahead of print].
2. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–72.
3. Food and Drug Administration. Alogliptin, “Other Reviews”. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000OtherRedt.pdf. Accessed 18 Aug 2014.
4. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. Vipidia (alogliptin). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002182/WC500152273.pdf. Accessed 18 Aug 2014.
5. Food and Drug Administration. Approved Drug Products. Alogliptin (2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Accessed 18 Aug 2014.
6. European Medicines Agency. Alogliptin product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002182/WC500152271.pdf. Accessed 18 Aug 2014.
7. Food and Drug Administration. Alogliptin Medical Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt.pdf. Accessed 18 Aug 2014.
8. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.
9. Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf. Accessed 18 Aug 2014.
10. National Institutes of Health. National Library of Medicine. MedlinePlus. ALT. http://www.nlm.nih.gov/medlineplus/ency/article/003473.htm. Accessed 18 Aug 2014.
11. The Merck Manual, Professional Edition. Normal Laboratory Values: Blood, Plasma, and Serum. http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html. Accessed 18 Aug 2014.